Literature DB >> 23623449

Negative symptom improvement during cognitive rehabilitation: results from a 2-year trial of Cognitive Enhancement Therapy.

Shaun M Eack1, Raquelle I Mesholam-Gately, Deborah P Greenwald, Susan S Hogarty, Matcheri S Keshavan.   

Abstract

Cognitive rehabilitation has shown beneficial effects on cognition in patients with schizophrenia, which may also help to improve negative symptoms due to overlapping pathophysiology between these two domains. To better understand the possible relationship between these areas, we conducted an exploratory analysis of the effects of Cognitive Enhancement Therapy (CET) on negative symptoms. Early course schizophrenia outpatients (n=58) were randomized to 2 years of CET or an Enriched Supportive Therapy (EST) control condition. Results revealed significant and medium-sized (d=0.61) differential improvements favoring CET in overall negative symptoms, particularly social withdrawal, affective flattening, and motor retardation. Neurocognitive improvement was associated with reduced negative symptoms in CET, but not EST patients. No relationships were observed between improvements in emotion processing aspects of social cognition, as measured by the Mayer-Salovey-Caruso Emotional Intelligence Test, and negative symptoms. CET represents an effective cognitive rehabilitation intervention for schizophrenia that may also have benefits to negative symptoms. Future studies specifically designed to examine negative symptoms during the course of cognitive rehabilitation are needed.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cognitive rehabilitation; Negative symptoms; Neurocognition; Psychosocial treatment; Schizophrenia; Social cognition

Mesh:

Year:  2013        PMID: 23623449      PMCID: PMC3732574          DOI: 10.1016/j.psychres.2013.03.020

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  43 in total

Review 1.  Brain reward circuitry: insights from unsensed incentives.

Authors:  Roy A Wise
Journal:  Neuron       Date:  2002-10-10       Impact factor: 17.173

2.  Treatment of schizophrenia negative symptoms: future prospects.

Authors:  Stephen M Erhart; Stephen R Marder; William T Carpenter
Journal:  Schizophr Bull       Date:  2006-02-21       Impact factor: 9.306

3.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

4.  One-year durability of the effects of cognitive enhancement therapy on functional outcome in early schizophrenia.

Authors:  Shaun M Eack; Deborah P Greenwald; Susan S Hogarty; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2010-05-15       Impact factor: 4.939

5.  Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial.

Authors:  Shaun M Eack; Deborah P Greenwald; Susan S Hogarty; Susan J Cooley; Ann Louise DiBarry; Debra M Montrose; Matcheri S Keshavan
Journal:  Psychiatr Serv       Date:  2009-11       Impact factor: 3.084

6.  Computerized cognitive training restores neural activity within the reality monitoring network in schizophrenia.

Authors:  Karuna Subramaniam; Tracy L Luks; Melissa Fisher; Gregory V Simpson; Srikantan Nagarajan; Sophia Vinogradov
Journal:  Neuron       Date:  2012-02-23       Impact factor: 17.173

Review 7.  The functional significance of social cognition in schizophrenia: a review.

Authors:  Shannon M Couture; David L Penn; David L Roberts
Journal:  Schizophr Bull       Date:  2006-08-17       Impact factor: 9.306

8.  The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia.

Authors:  R W Buchanan; D W Heinrichs
Journal:  Psychiatry Res       Date:  1989-03       Impact factor: 3.222

9.  Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.

Authors:  J P McEvoy; G E Hogarty; S Steingard
Journal:  Arch Gen Psychiatry       Date:  1991-08

10.  Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia.

Authors:  Viviane Labrie; Tatiana Lipina; John C Roder
Journal:  Psychopharmacology (Berl)       Date:  2008-07-03       Impact factor: 4.530

View more
  15 in total

1.  One-year randomized controlled trial and follow-up of integrated neurocognitive therapy for schizophrenia outpatients.

Authors:  Daniel R Mueller; Stefanie J Schmidt; Volker Roder
Journal:  Schizophr Bull       Date:  2015-02-22       Impact factor: 9.306

2.  Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia.

Authors:  Buranee Kanchanatawan; Solaphat Hemrungrojn; Supaksorn Thika; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-09-05       Impact factor: 5.590

3.  Early-Stage Negative Symptom Trajectories and Relationships With 13-Year Outcomes in First-Episode Nonaffective Psychosis.

Authors:  Wing Chung Chang; Ryan Wui Hang Ho; Jennifer Yee Man Tang; Corine Sau Man Wong; Christy Lai Ming Hui; Sherry K W Chan; Edwin M H Lee; Yi Nam Suen; Eric Y H Chen
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

4.  Social cognition, social competence, negative symptoms and social outcomes: Inter-relationships in people with schizophrenia.

Authors:  Marc Kalin; Sara Kaplan; Felicia Gould; Amy E Pinkham; David L Penn; Philip D Harvey
Journal:  J Psychiatr Res       Date:  2015-07-13       Impact factor: 4.791

Review 5.  Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions.

Authors:  Ori Elis; Janelle M Caponigro; Ann M Kring
Journal:  Clin Psychol Rev       Date:  2013-07-16

6.  Collection of developmental history in the evaluation of schizophrenia spectrum disorders.

Authors:  Angela M Reiersen
Journal:  Scand J Child Adolesc Psychiatr Psychol       Date:  2016

Review 7.  Recent advances in understanding schizophrenia.

Authors:  Chiara S Haller; Jaya L Padmanabhan; Paulo Lizano; John Torous; Matcheri Keshavan
Journal:  F1000Prime Rep       Date:  2014-07-08

8.  Development of the Positive Emotions Program for Schizophrenia: An Intervention to Improve Pleasure and Motivation in Schizophrenia.

Authors:  Alexandra Nguyen; Laurent Frobert; Iannis McCluskey; Philippe Golay; Charles Bonsack; Jérôme Favrod
Journal:  Front Psychiatry       Date:  2016-02-17       Impact factor: 4.157

9.  Neurocognitive Impairments in Deficit and Non-Deficit Schizophrenia and Their Relationships with Symptom Dimensions and Other Clinical Variables.

Authors:  Miao Yu; XiaoWei Tang; Xiang Wang; XiangRong Zhang; XiaoBin Zhang; WeiWei Sha; ShuQiao Yao; Ni Shu; XiangYang Zhang; ZhiJun Zhang
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

10.  Cognitive and clinical predictors of community functioning across the psychoses.

Authors:  Kathryn E Lewandowski; Talia R Cohen; Dost Ongur
Journal:  Psych J       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.